HGH Fragment 176-191 vs Pramlintide

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

HGH Fragment 176-191

HGH Fragment 176-191 is the fat-reducing portion of the growth hormone molecule. Unlike AOD-9604 (which has an additional tyrosine), this is the exact fragment of HGH responsible for lipolytic effects.

Full details →

Pramlintide

Pramlintide (Symlin) is a synthetic analog of amylin, FDA-approved as an adjunct to insulin therapy in type 1 and type 2 diabetes. It helps control post-meal blood sugar spikes and promotes modest weight loss.

Full details →

Side-by-Side Comparison

AspectHGH Fragment 176-191Pramlintide
MechanismMimics the lipolytic region of growth hormone, stimulating fat breakdown and inhibiting lipogenesis without affecting blood sugar or promoting growth. Works independently of GH receptors.Mimics amylin's effects: slows gastric emptying, suppresses glucagon secretion after meals, and promotes satiety through central mechanisms. Complements insulin therapy.
Typical DosageTypical dosing: 250-500mcg daily, often split into 2-3 doses. Usually administered on empty stomach, often with fasted cardio.Type 1: Start 15mcg before meals, titrate to 30-60mcg. Type 2: Start 60mcg, may increase to 120mcg. Always with meal containing 30+ grams carbs or 250+ calories.
AdministrationSubcutaneous injection. Best results when used fasted and combined with exercise. Avoid eating for 30 minutes post-injection.Subcutaneous injection immediately before major meals. Must reduce mealtime insulin by 50% when starting to prevent hypoglycemia. Never mix with insulin.
Side EffectsGenerally well-tolerated. May cause injection site irritation, temporary lethargy, or headache. Does not affect blood glucose significantly.Nausea (very common initially), headache, anorexia, vomiting, and abdominal pain. GI effects typically improve over time.
Best For

What They Have in Common

Both HGH Fragment 176-191 and Pramlintide are commonly used for:

Ready to Learn More?